OCTN1 variants shape innate immunity and predict individual response to anti-TNFα in ulcerative colitis patients: An exploratory study

Background Ulcerative colitis (UC) exhibits substantial heterogeneity in inflammatory pathways and therapeutic response. The organic cation transporter OCTN1 (SLC22A4) and its rs1050152 missense variant (L503F) have been implicated in innate immune activation and disease susceptibility. We investigated whether OCTN1 variants modulate monocyte inflammatory responses and predict clinical outcomes in UC patients treated with anti-tumor necrosis factor alpha (TNF alpha) agents.Methods We combined preclinical and clinical approaches. In THP-1 cells engineered for OCTN1 knockdown or variant-specific overexpression, and in primary monocytes isolated from genotyped donors and UC patients, we assessed by enzyme-linked immunosorbent assay and Western blot interleukin (IL)-1 beta production following bacterial stimulation (peptidoglycan, Fusobacterium nucleatum, Escherichia coli, Salmonella). In the clinical study, UC patients initiating anti-TNF alpha therapy were genotyped and evaluated for 1-year therapy persistence, steroid-free clinical remission, and endoscopic response. Logistic regression models were used to identify predictors of outcomes. An exploratory machine learning analysis (regularized logistic regression and neural networks) was performed to rank the variables contributing to each endpoint.Results OCTN1-deficient THP-1 cells showed markedly reduced interleukin-1 beta secretion, whereas the same cell line or primary monocytes carrying the 503F variant exhibited significantly enhanced cytokine release upon microbial stimulation. On the clinical side, 105 patients with UC were enrolled. The homozygous 503F genotype (TT) was strongly associated with higher rates of steroid-free remission, endoscopic response, and therapy persistence. Heterozygous carriers displayed intermediate outcomes. Machine learning models demonstrated moderate predictive performance (area under the curve 0.60-0.72), consistently ranking OCTN1 among relevant, though not dominant, determinants of therapeutic success.Conclusions The OCTN1 503F variant enhances interleukin-1 beta-mediated innate immune activation and is associated with improved long-term response to anti-TNF alpha therapy in UC. These findings support OCTN1 genotyping as a promising component of future precision medicine strategies in inflammatory bowel disease and warrant confirmation in larger prospective multicenter cohorts.The inflammatory bowel disease-associated 503F variant of the organic cation transporter OCTN1 promotes interleukin-1 beta production from leukocytes and predicts a better response to anti-tumor necrosis factor alpha therapy in patients with ulcerative colitis. Machine learning confirms this finding.